Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
April 16 2024 - 7:30AM
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative
medicine company focused on the development, manufacture, and
commercialization of product solutions for the Advanced Wound Care
and Surgical & Sports Medicine markets, today announced that
first quarter of fiscal year 2024 financial results will be
reported after the market closes on Thursday, May 9th.
Management will host a conference call at 5:00
p.m. Eastern Time on May 9th to discuss the results of the quarter
and provide a corporate update with a question and answer session.
Those who would like to participate may access the live webcast
here, or access the teleconference here. The live webcast can also
be accessed via the company’s website at
investors.organogenesis.com. The webcast will be archived on the
company website for approximately one year.
About Organogenesis Holdings
Inc. Organogenesis Holdings Inc. is a leading regenerative
medicine company focused on the development, manufacture and
commercialization of solutions for the advanced wound care and
surgical and sports medicine markets. Organogenesis offers a
comprehensive portfolio of innovative regenerative products to
address patient needs across the continuum of care. For more
information, visit www.organogenesis.com.
Investor Inquiries:
ICR Westwicke
Mike Piccinino, CFA
OrganoIR@westwicke.com
Press and Media Inquiries:
Organogenesis
communications@organo.com
Organogenesis (NASDAQ:ORGO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Organogenesis (NASDAQ:ORGO)
Historical Stock Chart
From Jul 2023 to Jul 2024